Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Slides:

Advertisements

Similar presentations

Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Lauranne A.A.P. Derikx, Loes H.C.

Advertisements

The Role of Psychosocial Care in Adapting to Health Care Reform

Abnormal Liver Tests and Fatty Liver on Ultrasound

Ashwin N. Ananthakrishnan, Millie D. Long, Christopher F

Saurabh Dawra, Vishal Sharma, Usha Dutta

Volume 138, Issue 2, Pages (February 2010)

Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case–Control and Cohort Studies Guillaume Pineton de Chambrun, Luc.

Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial Maria Bomme, Jane Møller Hansen,

Nitsan Maharshak, Scott E. Plevy

Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure Stephen J.D. O'Keefe, Palle B. Jeppesen,

Volume 135, Issue 4, Pages (October 2008)

Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis Alexander C. Ford, Khurram J. Khan, William.

Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation- predominant Irritable Bowel Syndrome: A Randomized Controlled Trial

Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set Christopher.

Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure Stephen J.D. O'Keefe, Palle B. Jeppesen,

Morgagni's Hernia Clinical Gastroenterology and Hepatology

A Shocking Cystory Clinical Gastroenterology and Hepatology

Volume 133, Issue 1, Pages (July 2007)

Immune Reconstitution Inflammatory Syndrome of the Small Bowel in a Human Immunodeficiency Virus–Negative Patient Severin Daum, Christoph Loddenkemper,

Prevalence of Irritable Bowel Syndrome–type Symptoms in Patients With Celiac Disease: A Meta-analysis Anita Sainsbury, David S. Sanders, Alexander C.

Laurent Peyrin-Biroulet, Julián Panés, William J

Rebekah S. Wieland, Richard S. Zubarik, Maryam J. Zenali

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease Garret Cullen, Denise Keegan, Hugh.

Computed Tomography Enterography Detects Intestinal Wall Changes and Effects of Treatment in Patients With Crohn's Disease David H. Bruining, Edward.

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean–Frédéric Colombel, William.

Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study Henry P. Parkman,

Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Personalizing Colorectal Cancer Screening: A Systematic Review of Models to Predict Risk of Colorectal Neoplasia Gene K. Ma, Uri Ladabaum Clinical Gastroenterology.

Patrick B. Allen, Paul J. Kettle, Inder Mainie

Volume 130, Issue 2, Pages (February 2006)

Volume 155, Issue 1, Pages (July 2018)

Volume 147, Issue 3, Pages e3 (September 2014)

Alan J. Wigg, Rosemary McCormick, Rachel Wundke, Richard J. Woodman

AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review Jean-Frederic Colombel,

Volume 146, Issue 1, Pages e1 (January 2014)

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab Fernando.

Volume 132, Issue 5, Pages (May 2007)

Abnormal Liver Tests and Fatty Liver on Ultrasound

Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis Gary R. Lichtenstein,

William J. Sandborn, Stefan Schreiber, Brian G

Volume 145, Issue 5, Pages e5 (November 2013)

Bara Erhayiem, Rajpal Dhingsa, Christopher J

Volume 132, Issue 1, Pages (January 2007)

Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study Timna Naftali, Lihi Bar-Lev Schleider,

David H. Bruining, William J. Sandborn

Najat Mourra, Nikias Colignon Clinical Gastroenterology and Hepatology

Peter Bytzer Clinical Gastroenterology and Hepatology

Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging Konstantinos Karmiris, Didier.

Rebecca M. Lovell, Alexander C. Ford

Issue Highlights Clinical Gastroenterology and Hepatology

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials Edward.

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Volume 142, Issue 5, Pages e2 (May 2012)

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Walter Reinisch, Jean-Frederic Colombel, William J

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Minimal-Change Esophagitis on Narrow-Band Imaging

Christopher Hung, Desmond Leddin

Volume 142, Issue 2, Pages e3 (February 2012)

Coagulation in Liver Disease: A Guide for the Clinician

Coloduodenal Fistula in Crohn’s Disease

Adverse Outcomes: Why Bad Things Happen to Good People

Medical Therapy for Refractory Pediatric Crohn’s Disease

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months Gary R. Lichtenstein, Ole Ø. Thomsen,

The Role of Psychosocial Care in Adapting to Health Care Reform

Richard A. Hansen, Gerald Gartlehner, Gregory E. Powell, Robert S

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

Presentation transcript:

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert D'Haens, Jean–Frédéric Colombel, Severine Vermeire, Krassimir Mitchev, Corinne Jamoul, Richard N. Fedorak, Martina E. Spehlmann, Douglas C. Wolf, Scott Lee, Paul Rutgeerts Clinical Gastroenterology and Hepatology Volume 8, Issue 8, Pages 688-695.e2 (August 2010) DOI: 10.1016/j.cgh.2010.04.021 Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 1 Study flow diagram. ae, adverse event; loe, lack/loss of efficacy; ltfu, lost to follow-up evaluation; q2w, every 2 weeks; q4w, every 4 weeks; woc, withdrawal of consent. Clinical Gastroenterology and Hepatology 2010 8, 688-695.e2DOI: (10.1016/j.cgh.2010.04.021) Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Response and remission rates (A) over the open-label induction phase (n = 539) and (B) at week 26 (n = 329). Clinical Gastroenterology and Hepatology 2010 8, 688-695.e2DOI: (10.1016/j.cgh.2010.04.021) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 CDAI scores over time (n = 329). Clinical Gastroenterology and Hepatology 2010 8, 688-695.e2DOI: (10.1016/j.cgh.2010.04.021) Copyright © 2010 AGA Institute Terms and Conditions